Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,599.00
Bid: 1,594.50
Ask: 1,595.50
Change: -19.00 (-1.17%)
Spread: 1.00 (0.063%)
Open: 1,608.00
High: 1,615.00
Low: 1,575.00
Prev. Close: 1,618.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Inflation, housing market: Same as it ever was

Wed, 13th Jan 2021 16:06

* Major US indexes gyrate, now mixed: Nasdaq, S&P gain, Dow
slips

* Utilities lead S&P sector gainers; materials weakest group

* Euro STOXX 600 edges higher

* Dollar, gold rise; crude dips

* US 10-Year Treasury yield ~1.11%

Jan 13 - Welcome to the home for real-time coverage of
markets brought to you by Reuters reporters. You can share your
thoughts with us at markets.research@thomsonreuters.com

INFLATION, HOUSING MARKET: SAME AS IT EVER WAS (1105
EST/1605 GMT)

U.S. data released on Wednesday shocked exactly no one with
the alarming news that inflation is cool and the housing market
is hot - same song, thousandth verse.

The prices American consumers pay for a basket of items -
the consumer price index (CPI) - increased by 0.4%
in December according to the Labor Department, inline with
consensus and an acceleration from November's 0.2% growth.

The gain was primarily driven by an 8.4% jump in gasoline
prices. Stripping away volatile food and energy prices,
so-called "core CPI" grew by a paltry 0.1%.

Year over year, core CPI growth held firm at 1.6%, well
below the U.S. Federal Reserve's average annual inflation target
of 2%. While the Fed's preferred inflation yardstick is the PCE
index, the languid inflation numbers from nearly every major
indicator suggests the central bank's easy monetary policy isn't
going anywhere for the time being.

"Sluggish aggregate demand keeps underlying price pressures
at bay," writes Kathy Mostjancic, chief U.S. financial economist
at Oxford Economics (OE). "Moreover, the ongoing pandemic
continues to depress gains in core service prices."

It's always a good idea to revisit our old friend The Misery
Index. While the MI takes different forms, it's generally
considered to be the sum of the unemployment rate and annual
inflation growth.

As seen in the graphic below, the MI increased in 2020's
final month for the first time since April:

Finally, demand for home loans jumped by an impressive 16.7%
last week, according to the Mortgage Bankers Association (MBA).

Even with the average 30-year fixed contract rate
inching up 2 basis points to a still-historically-low 2.88%,
refi applications, which accounted for 74.8% of the
total, surged by more than 20%. Demand for loans to purchase
homes rose by 8%.

"Sustained housing demand continued to support purchase
growth, with activity up nearly 10 percent from a year ago,"
said Joel Kan, Associate Vice President of Economic and Industry
Forecasting at MBA.

But can the housing market, the darling of the U.S. economic
recovery, continue its impressive run? Perhaps not.

"We expect some moderation in the pace of home sales from
the late 2020 pace, as rising home prices and limited
inventories constrain sales," says Nancy Vanden Houten, lead
economist at OE.

Investors had difficulty deciding on whether to accentuate
the positive or the negative in morning trading, with the major
U.S. indexes ping-ponging between red and green.

Chips seem determined to have a good day, while
economically sensitive small caps and transports
are easing off Tuesday's record closing highs.

(Stephen Culp)

*****

EUROPEAN STOCKS: UNLOVED FOR THE PAST TWO DECADES, WHAT
ABOUT THE NEXT? (1045 EST/1545 GMT)

While Wall Street and Asian stocks are at all-time highs,
Europe is clearly lagging and has been for the past 20 years.

The old continent's share in the value of global equities
has almost halved over the past two decades, to 17% from over
30%, as per BofA Global Research.

The U.S. bank blames it on the absence of FAANGs, bigger
exposure to cheap sectors like banks and energy, aging
population, pressures from de-globalisation and climate change,
slower GDP growth versus rest of the developed world.

Apparently, Apple sells more watches than the
entire Swiss watch industry, and Cisco's market cap is
more than that of leading telecom service providers in UK,
France, Spain, Italy and Switzerland, combined, according to the
note.

What does the future look like for European investors? BofA
lists a handful of sectors that could shape the markets in the
next decade.

FANGMAN to GRANS: While U.S. remains a FANGMAN
market(Facebook, Amazon, Alphabet,
Microsoft, Apple, Netflix), Europe is
dominated by GRANS (GlaxoSmithKline, Roche,
AstraZeneca, Novartis, Sanofi).
Healthcare has been among the sectors whose markets weightings
have grown in the wake of the pandemic.

CLIMATE ACTION: Eight of the top 10 clean energy companies
by market cap are in Europe, which is also the undisputed leader
of ESG markets.

LUXURY: Luxury companies in Europe are worth more than its
autos sector, while in 2009 they were worth less than one-third;
LVMH is valued more than 4x Daimler, the largest
European carmaker.

GOLDEN AGE FOR EU CLEANTECH: 85% of Europe's electricity is
expected to be from zero-carbon sources by 2030 vs. 57% in 2020;
BofA sees tailwind from economics, policy, funding, tech
innovation and consumer adoption.

Even so, BofA says Europe's pro-cyclical nature and a weak
domestic growth means that European EPS only outperforms during
periods of strong global growth, and it's lack of exposure to
high-growth sectors like technology will drive its structural
underperformance in future.

(Sruthi Shankar)

*****

U.S. STOCKS WAFFLE, THEN HEAD SOUTH (1008 EST/1508 GMT)

Wall Street waffled on Wednesday after the opening bell,
strobing between green then red - but seemed to decide, a
half-hour into the session, to settle in negative territory.

There was little in the way of a catalyst to turn investor
moods sour or sweet. The ongoing vaccine rollout and
expectations for more generous fiscal stimulus from the incoming
Biden administration was again offset by the resurgent pandemic
and the unfolding drama in Washington.

The U.S. House of Representatives is expected to vote for
the second time within 12 months to impeach President Donald
Trump, this time for inciting an insurrection.

That insurrection caught the attention of U.S. Federal
Reserve officials, who said on Tuesday that while concerns about
continued violence pose a risk, but the transition to a new
administration on Jan. 20, and a likely accelerating vaccine
rollout have left them optimistic.

On the economic front, CPI data appeared to confirm tepid
inflation that can keep the Fed's monetary policy accommodative
for the foreseeable future.

In a reversal from Tuesday, economically sensitive small
caps and transports are underperforming the
broader market.

Here's your opening snapshot:
(Stephen Culp)

*****

TECH VS FINANCIALS: COMING BACK TO EARTH (0900 EST/1400 GMT)

After an unprecedented streak of consecutive higher monthly
closes that ended in August of last year, the S&P 500 tech
sector / S&P 500 financial sector ratio has
been coming back to earth.

This, as value took the reins from growth.

Indeed, the tech / financials ratio ended at 5.23 in August,
after having logged 11-straight higher monthly closes. (Click on
chart below)

That's one more month than the 10-month win streak the ratio
recorded into the Nasdaq/tech sector October 2007 top.
It was also this ratio's longest streak of higher monthly closes
using Refinitiv data back to 1989.

Additionally, through August, the ratio ended above its
upper monthly Bollinger Band (BB) for eight straight months
(more than two standard deviations above its 20-month moving
average). That was also its longest such streak going back to
1989. Thus, the ratio appeared especially high on a relative
basis.

With September's downtick, the ratio came back inside the
upper monthly BB, suggesting potential for a more significant
reversal.

Now, at 4.36, the ratio is on track to fall for a 5th
straight month. A continued decline to even just meet the rising
20-month moving average, now around 3.99, would suggest
additional tech underperformance relative to financials, and
with this, likely further growth underperformance vs value.

(Terence Gabriel)

*****

FOR WEDNESDAY'S LIVE MARKETS' POSTS PRIOR TO 0900 EST/1400
GMT - CLICK HERE:

(Terence Gabriel is a Reuters market analyst. The views
expressed are his own)

More News
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
2 May 2024 19:57

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.

Read more
2 May 2024 09:48

LONDON BROKER RATINGS: Deutsche Bank likes TP ICAP but says sell CMC

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 May 2024 19:39

Bird flu testing shows more dairy products are safe, US FDA says

CHICAGO, May 1 (Reuters) - Preliminary results of tests on additional dairy products show that pasteurization inactivates the bird flu virus, the U.S. Food and Drug Administration said on Wednesday.

Read more
1 May 2024 17:31

UK's FTSE 100 slips ahead of Fed outcome, energy stocks weigh

FTSE 100 down 0.3%, FTSE 250 off 0.2%

*

Read more
1 May 2024 16:56

LONDON MARKET CLOSE: FTSE 100 down ahead of US interest rate decision

(Alliance News) - Stock prices in London closed mostly in the red on Wednesday, as investors eye the latest interest rate decision from the US Federal Reserve this evening.

Read more
1 May 2024 16:42

London close: Stocks fall ahead of US Fed decision

(Sharecast News) - London markets closed lower on Wednesday, as investors digested the latest UK manufacturing data and anticipated an impending policy announcement from the US Federal Reserve.

Read more
1 May 2024 11:55

LONDON MARKET MIDDAY: FTSE 100 treads water as Fed takes centre-stage

(Alliance News) - London's FTSE 100 traded off session highs heading into Wednesday afternoon, as some pre-Federal Reserve decision nerves kicked in.

Read more
1 May 2024 10:54

GSK raises profit outlook on strong vaccine, HIV drug sales

FY profit forecast raised to 8-10%

*

Read more
1 May 2024 08:57

LONDON MARKET OPEN: FTSE 100 shakes off New York slump before Fed

(Alliance News) - Stock prices in London opened mixed on Wednesday, with the FTSE 100 brushing off some pre-Federal Reserve decision trepidation to record an early rise, while the dollar climbed on the expectation that Jerome Powell will sound hawkish in his press conference later.

Read more
1 May 2024 08:50

TOP NEWS: GSK expects momentum to continue after strong first quarter

(Alliance News) - GSK PLC on Wednesday raised its annual earnings forecast, and said it expects sales growth at the top-end of guidance, after a "strong" start to the year.

Read more
1 May 2024 07:46

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

Read more
1 May 2024 07:36

GSK lifts annual guidance on strong virus treatment sales

(Sharecast News) - UK pharmaceutical giant GSK lifted annual profits guidance on Wednesday, as it pinned its hopes on demand for its respiratory virus and shingles treatments.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.